| abstract |
The use of an anti-connexin 43 polynucleotide for the treatment of abnormal or excessive scars. In humans and other mammals, wounds induce an organized and complex cascade of cellular and biochemical events, resulting in wound healing in most cases. Scars are the result of a healed wound, disease lesion or surgery. Hypertrophic and keloid scars occur when the tissue response is disproportionate to the amount of scar tissue required for normal repair and healing. The present invention relates to methods, compounds, compositions, kits and products comprising anti-connexin polynucleotides for preventing and / or treating abnormal scars, including keloid scars, hypertrophic scars, atrophic scars, and diffuse scars. . [Selection figure] None |